NCT04071119 is a Phase 1 clinical trial of Oxytocin nasal spray in Alcohol Use Disorder, sponsored by Brown University.

Who is sponsoring NCT04071119?

NCT04071119 is sponsored by Brown University.

What drugs are being tested in NCT04071119?

Interventions in NCT04071119: Oxytocin nasal spray, Placebo.

What condition does NCT04071119 study?

NCT04071119 studies Alcohol Use Disorder, Smoking.

Is NCT04071119 still recruiting?

NCT04071119 is currently completed. Last updated 14 May 2024.

Last reviewed 2024-05-14 · How we verify

NCT04071119

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alcohol and Cigarette Craving During Oxytocin Treatment

Completed Phase 1 Last updated 14 May 2024

What this trial tests

Phase 1 trial testing Oxytocin nasal spray in Alcohol Use Disorder in 19 participants. Completed in 2 April 2024.

Timeline

9 November 2020

Primary endpoint
2 April 2024

2 April 2024

Quick facts

Lead sponsor	Brown University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	19
Start date	9 November 2020
Primary completion	2 April 2024
Estimated completion	2 April 2024
Sites	1 location across United States

Drugs / interventions tested

Oxytocin nasal spray — full drug profile →
Placebo

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Smoking — all drugs for Smoking →

Sponsor

Brown University

Who can join

Adults 18 to 55, any sex, with Alcohol Use Disorder or Smoking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This proposed research seeks to examine the behavioral and neural substrates of intranasal oxytocin compared to placebo on alcohol cue-induced alcohol and cigarette craving smokers with an alcohol use disorder (AUD). Non treatment-seeking smokers with an AUD will be recruited to participate in a between-subjects, placebo-controlled, randomized pilot functional magnetic resonance imaging (fMRI) study. Participants will undergo an fMRI scan in conjunction with an alcohol-olfactory cue-reactivity task. Secondary assessments will include alcohol and cigarette craving, alcohol and cigarette consumption, physiological measures (heart rate and blood pressure) and mood measures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Orphan peptide and G protein-coupled receptor signalling in alcohol use disorder.
Anversa RG, Maddern XJ, Lawrence AJ, Walker LC. · · 2024 · cited 4× · PMID 38073127 · DOI 10.1111/bph.16301

Verify or expand the search:

Other trials of Oxytocin nasal spray

Trials testing the same drug.

NCT07162584 — Oxytocin and Human Defensive Responses in a Dynamic Situation · NA · recruiting
NCT06194851 — Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD · Phase 2 · recruiting
NCT05934812 — Intranasal Oxytocin in Youth With Autism · Phase 2 · not yet recruiting
NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
NCT06332066 — Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness · Phase 1 · unknown

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other Brown University trials

Trials by the same sponsor.

NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption · Phase 2 · recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults · NA · recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment · Phase 4 · not yet recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04071119 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 14 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04071119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing